Stockreport

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Corporation  (RLYB) 
PDF — CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 —— $75.1 Million in Cash, Cash Equivalents, and Marketable Securit [Read more]